What is the main reason for the failed acquisition of JenaValve?

The U.S. Federal Trade Commission (FTC) sought an injunction, and the U.S. District Court for the District of Columbia granted it, blocking the acquisition. The specific reasons cited by the FTC for opposing the deal are not detailed in this 8-K filing.

What are the immediate financial implications of this blocked acquisition for Edwards Lifesciences?

This 8-K filing does not detail specific financial implications such as termination fees or impact on financial statements. However, the inability to acquire JenaValve means the expected synergies and market expansion from the deal will not materialize, potentially impacting future growth projections.

Will Edwards Lifesciences pursue other acquisitions after this setback?

This filing does not provide information on future acquisition plans. Investors will need to monitor future company communications and SEC filings for updates on the company's inorganic growth strategy.

What is the significance of the information not being 'filed' under Section 18 of the Exchange Act?

Information furnished under Item 7.01, like this announcement, is generally considered 'furnished' rather than 'filed'. This means it is not subject to the strict liability provisions of Section 18 of the Securities Exchange Act of 1934, which pertains to the accuracy of filed documents. However, it is still important information for investors.

EW 8-K: Regulation FD — Jan 12, 2026

Summary

Edwards Lifesciences Corporation (EW) announced on January 11, 2026, that its proposed acquisition of JenaValve Technology, Inc. has been blocked by a preliminary injunction granted by the U.S. District Court for the District of Columbia at the request of the U.S. Federal Trade Commission (FTC). Consequently, the transaction will not proceed as planned. This development is a significant setback for Edwards Lifesciences' strategic growth initiatives and integration plans that hinged on the acquisition of JenaValve. Investors should focus on the implications of this failed acquisition, including potential impacts on future revenue streams, market positioning, and the company's capital allocation strategy. While the financial terms of the deal and any termination fees are not detailed in this 8-K, this event signifies a need for management to reassess its inorganic growth strategy and potentially seek alternative avenues for market expansion or product portfolio enhancement. The company's stock performance may be influenced by market reaction to this news and any subsequent management commentary.

Key Highlights

1Edwards Lifesciences' proposed acquisition of JenaValve Technology, Inc. has been blocked by a court injunction.
2The injunction was granted by the U.S. District Court for the District of Columbia following a motion by the U.S. Federal Trade Commission.
3As a result of the injunction, Edwards Lifesciences will not be acquiring JenaValve.
4The company filed an 8-K on January 11, 2026, to disclose this material event.
5The press release announcing this development is attached as Exhibit 99.1 to the filing.

Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Jan 12, 2026)

Summary

Key Highlights

Frequently Asked Questions